Stonemor Inc
Change company Symbol lookup
Select an option...
STON Stonemor Inc
$NQDM15LMCADN Nasdaq Developed Markets Telecommuni
BFZ BlackRock California Municipal Income Trust
CAR Avis Budget Group Inc
GIS General Mills Inc
VLN Valens Semiconductor Ltd
CIF MFS? Intermediate High Income Fund
LVOXW LiveVox Holdings Inc *W EXP 06/18/2026
SASR Sandy Spring Bancorp Inc
SWKH SWK Holdings Corp

Consumer Discretionary : Diversified Consumer Services | Small Cap Value
Company profile

Stonemor Inc. is a provider of funeral and cemetery products and services in the death care industry. The Company's segments include Cemetery Operations and Funeral Home Operations. Cemetery Operations segment consists of sale of cemetery merchandise, which includes markers, bases, vaults, caskets and cremation niches and its cemetery services, which include opening and closing services, cremation services and fees for the installation of cemetery merchandise. Funeral Home Operations segment consists of sales of funeral home merchandise, which includes caskets and other funeral related items and service, which include services such as family consultation, the removal of and preparation of remains and the use of funeral home facilities for visitation and prayer services. Funeral Home Operations segment also include the sale of term and whole life insurance on an agency basis, in which it earn a commission from the sales of these insurance policies.

Closing Price
Day's Change
-0.02 (-0.79%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Allowing people to mix COVID-19 vaccines could cut into Pfizer and Moderna's revenue next year

8:13 am ET October 11, 2021 (MarketWatch)

Jaimy Lee

AstraZeneca, J&J, Moderna, and Pfizer are expected to bring in $46 billion in revenue for their COVID-19 shots in 2022

Expect to see data this month from several clinical trials that are trying to establish if "mixing and matching" different COVID-19 vaccines is safe and effective or if it's better to get the same booster as the one used in the primary series of shots.

There are two ways to think about the type of COVID-19 booster you can get: in one scenario, you get a homologous booster, which is the same shot you got for the initial series. A heterologous, or "mix-and-match" booster, lets you get a different vaccine based on availability or improved efficacy.

This is an important scientific distinction that will likely be used to further inform how COVID-19 booster shots will be rolled out in the U.S.

"There will be situations for one reason or another where a person may not have the availability to be boosted with the same product that they were originally vaccinated with," Dr. Anthony Fauci, President Joe Biden's chief medical adviser, told McClatchy last month.

But analysts say mixing COVID-19 shots could also dampen revenue projections for the vaccine market's leaders.

"If ongoing mix-and-match trials show that the late entrants' products are as effective at boosting as the original innovator vaccines themselves, then these companies stand to gain potentially meaningful near-term revenues and will almost certainly take significant share of whatever tail of future COVID vaccine revenue exists," SVB Leerink analyst Geoffrey Porges told investors this week.

Four COVID-19 vaccine makers -- AstraZeneca (AZN.LN), Johnson & Johnson (JNJ), Moderna Inc. (MRNA), and Pfizer Inc. (PFE), the market leaders -- are expected to bring in $46 billion in revenue for their COVID-19 shots in 2022.

Roughly $19 billion of the sales generated so far over the past year came from selling the initial doses of their shots.

What to expect from the "mix-and-match" clinical trials

Right now, only recipients of the BioNTech SE (BNTX) and Pfizer vaccine can get a booster shot (based on their health status, age, and line of work) in the U.S. The people who got the Moderna or J&J shots are still waiting on regulators to decide if they can get a booster.

Those are considered homologous boosters.

But other research is under way assessing whether it's okay to mix vaccines, and there are already some preliminary studies that indicate mixing vaccines is safe and could prompt a stronger immune response in some cases.

A U.S. study, which is being conducted by the National Institutes of Health and is testing a Moderna booster with other types of vaccines, is expected to make its findings public on Oct. 15 at a Food and Drug Administration advisory meeting assessing J&J's booster application.

Results are also expected sometime this month from a U.K. trial called Cov-Boost.

A preprint published in June out of the U.K. found that mixing the BioNTech/Pfizer and AstraZeneca/University of Oxford vaccines triggered better immunity than using the AstraZeneca shots alone. Researchers in Germany said, also in June, that mixing the same vaccines as the U.K. could "improve immunogenicity and to mitigate potential intermittent supply shortages for individual vaccines."

How mixing vaccines can impact revenue projections for COVID-19 vaccine makers

Depending on how the data shakes out, it could have a big impact on the market share held by the leading COVID-19 vaccine makers.

If clinical data shows that it's safe and effective to use a different type of COVID-19 booster, that could allow some of the smaller companies developing still-investigational shots to gain entry and a slice of market share, according to Porges.

"If mix-and-match boosting is found to be as effective or better than three doses of an mRNA vaccine, PFE and MRNA may capture less of the long tail of COVID vaccine revenues than currently priced in," he wrote, "and companies like Sanofi, Novavax, Valneva, and Clover Biopharmaceuticals could participate in this market."Sanofi (SAN.FR) is currently testing the experimental recombinant protein vaccine and booster it developed with GlaxoSmithKline in Phase 3 clinical trials. (Sanofi said Sept. 28 it would stop developing its mRNA shot.)

Novavax Inc.'s (NVAX) COVID-19 vaccine candidate is expected to soon be submitted to the FDA for authorization.

Valneva SE is a French biotech that is still evaluating its experimental COVID-19 shot in clinical trials, while Clover Biopharmaceuticals is a privately held Chinese biotech with a vaccine candidate in Phase 2/3 trials.

So far this year, U.S.-listed shares of AstraZeneca have gained 18.8%, J&J's stock has edged up 0.4%, Moderna shares have soared 201.8%, and Pfizer's stock has gained 13.5%. The S&P 500 is up 15.7% in 2021.

-Jaimy Lee


(END) Dow Jones Newswires

October 11, 2021 08:13 ET (12:13 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.